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axis plays a pivotal role in critical illness, with a derangement
leading to profound changes in metabolism. Protein wasting with
skeletal muscle loss, delayed wound healing, and impaired
recovery of organ systems are some of the most feared conse-
quences. The use of human recombinant Growth Hormone (rhGH)
and Insulin-like Growth Factor-1 (IGF-1) – alone and in combina-
tion – has been studied extensively in preclinical and clinical trials.
This article reviews the current knowlegde and clinical practice of
the use of rhGh and IGF-1 in critically ill patients, with a special
focus on the trauma and burns patient population.
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The elevation of catecholamine, cortisol, and glucagon levels are a hallmark of the critically ill
patient. In the population of critically ill and thermally injured patients, this derangement perpetuates
the profound changes in metabolic rates, growth and pathophysiology. The use of human recombinant
Growth Hormone (rhGH) and Insulin-like Growth Factor-1 (IGF-1) – alone and in combination – has
been studied extensively in preclinical and clinical trials. This article reviews the current knowlegde
and clinical practice of the use of rhGh and IGF-1 in critically ill patients, with a special focus on the
trauma and burns patient population.Fax: þ1 409 770 6919.
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IGF-1 is a 7.7-kDa single-chain polypeptide of 70 amino acids that is similar in sequence to
proinsulin and is greater than ninety-ﬁve percent bound to one of six IGF binding proteins 1–6
(IGFBPs).1,2 IGF-1 is also an anabolic growth factor that is known to improve the metabolic rate,
gut mucosal function, and protein loss after traumatic injury.3 This hormone is synthesized by
hepatocytes in response to growth hormone and has been shown to stimulate amino acid
uptake, incorporate itself into liver and muscle protein, and also decrease muscle protein
degradation.4,5 In addition, animal models have demonstrated that IGF-1 acts to mediate growth
hormone action during the hypermetabolic state by improving cell recovery to enhance wound
healing, improve the immune response, and attenuate lean body mass loss and the acute phase
response, all without the harmful effects associated with growth hormone treatment alone.6,7
The signal pathway by which IGF-1 modulates the hepatic acute phase response is still
unknown.
Approximately ninety percent of IGF-1 is bound to IGFBP-3, which serves as its major consti-
tutive binding protein. The other binding proteins are relatively small, but have various physiologic
functions. IGFBP-5, for example, is also capable of forming a complex with IGF-1, extending its half-
life as does IGFBP-3 when bound to it. On the other hand, the binary complexes of IGFBP-1, 2, 4,
and 6 bind to IGF-1 to increase its bioavailability, allowing it to cross the endothelial barrier more
easily. During acute critical illness, IGFBP-3 and IGF-1 serum levels increase, while IGFBP-1 levels
decrease along with protease activity. This fall is thought to be due to critical illness associated
protease activity, which leads to changes in IGF-1 clearance rates. Alternately, low serum levels of
IGF-1, as seen during critical illness, leads to a decrease in circulating levels of IGFBP-1, but levels of
IGFFBP-1, 2, 4, and 6 are elevated, as they are not directly regulated by growth hormone [Mesotten,
2006 #2107]. Another possible explanation for the reduction of circulating IGF-1 levels found
during critical illness is that nutritional deﬁciency leads to alterations in cytokine and endotoxin
activity, therefore, decreasing the number of hepatic growth hormone receptors. This theory is
substantiated by evidence that IGF-1 increases hepatocyte proliferation and liver protein synthesis
and, therefore, attenuates the hypermetabolic response and diminishes the negative nitrogen
balance.8 In addition, the fasting state experienced during critical illness, secondary to the intol-
erance of enteral feeds, is reportedly associated with abnormally low levels of IGF-1.7 This state is
reproduced with exogenous growth hormone treatment and persists despite parenteral nutrition.
Research with unbound IGF-1 is limited by its side effects, which include hypoglycemia, mental
status changes, electrolyte imbalances, edema, fatigue, and headaches.9,10 These reactions occur
secondary to the need to provide large doses of IGF-1 in order to overcome intracellular feedback
signals and achieve biological efﬁcacy.11 The required doses of IGF-1 needed to observe a physio-
logic effect are potentially decreased with the use of IGF-1 bound to protein 3.12
Recombinant IGF-1 (binding protein) and gene transfer
Gene transfection using viruses as delivery vectors have been used in the treatment of a variety
of clinical disorders for decades. Unfortunately, the potential dangers associated with this method
have made it relatively undesirable.13 Researchers attempted to bypass these problems with the use
of deoxyribonucleic acid (DNA), either naked or plasmid constructs, but have been met with
inefﬁcient results, likely secondary to the fragility of the DNA constructs.14 The discovery of lipo-
somes with non-viral complementary DNA (cDNA) together with cytomegalovirus promoters has
provided similar success in increasing the efﬁcacy and transgenic expression levels to those seen
with the use of adenovirus constructs. This has been found to be more successful for the transfer of
genes and is associated with several advantages, such as resulting in robust, prompt, and transient
localized gene expression, without triggering immunological responses or tachyphylaxis.15–18 IGF-1
gene transfer became an area of interest secondary to the ability of IGF-1 to ameliorate the
inﬂammatory signaling cascade, as well as its association with the stimulation of wound heal-
ing.16,19 The use of this therapy would be most applicable in patient populations such as those with
skin disorders and burns.
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Gut mucosal barrier function has become an area of research interest since it became a potential
etiology related to the inﬂammatory response involved in multiple organ failure syndrome.20,21
Historical literature has shown numerous times that after severe injury (ie: burn, wound sepsis,
shock, or endotoxemia), gut mucosal atrophy occurs, causing increased mucosal permeability.22,23 The
presence of large burns causes gut atrophy; therefore, increasing the permeability of the gut to
macromolecules, leading to bacterial translocation.24 Large burns are also associated with a catabolic
and inﬂammatory state, which subsequently causes difﬁculty maintaining adequate nutrition. These
factors all appear to be involved in the suppression of growth hormone’s stimulation of hepatic IGF-1
production. Ultimately, IGF-1 serum levels are decreased.25,26 This had led to studies evaluating the
beneﬁts of IGF-1 administration on gastrointestinal function during injury. Strock and Herndon (1990)
used a burn model to demonstrate that IGF-1 treatment may attenuate the catabolic response, as seen
with a reduction in weight loss and basal metabolic expenditure.27 Huang and Herndon (1993) used
a rodent burn model to demonstrate that gut mucosal barriers fail after signiﬁcant trauma, causing
bacterial translocation. Treatment with IGF-1 resulted in a decrease in bacterial translocation to
mesenteric lymph nodes, and suggested that the distal small bowel may be less sensitive to IGF-1 than
proximal small bowel.28 More recently, IGF-1 treatment has been found to result in decreased gut
mucosal atrophy and increased body weight.7
IGF-1 in thermal injury
Anabolic hormone levels after severe burns has been studied extensively. The tissue damage
induced by thermal injury is due to membrane destabilization and energy depletion at the cellular
level. This ultimately leads to delayed cell death secondary to tissue necrosis, inﬂammation, ischemia,
and reperfusion inadequacies. During recovery from burn injury, cell proliferation, angiogenesis, and
re-epithelialization are abundant. Recovery after burns can potentially be improved by blocking the
initiation of the inﬂammatory cascade, which ultimately targets the extracellular matrix and blood/
parenchymal cells, thus prolonging the hypermetabolic response and immune dysfunction.29 It has
been demonstrated that burn injury results in a decrease in serum IGF-1 levels to 3–4 times below
normal, and that these levels remain low for up to 40 days after injury, despite adequate nutrition.30
The importance of this information is validated by research showing that IGF-1 expression appears
to select against pro-apoptotic processes associated with the inﬂammatory cascade.31 In a burn rat
model, IGF-1 infusion was found to result in the maintenance of serum IGF-1 levels, body weight
increase, and a decrease in oxygen consumption.27 Burn patient studies have also shown that exoge-
nous IGF-1 treatment for three days results in decreased protein oxidation and increased glucose
oxidation.32
IGF-1 in critical illness (trauma, shock and sepsis)
The process of tissue trauma, regardless of etiology, is associated with cell proliferation, angio-
genesis, and re-epithelialization, which is subsequently associated with extracellular matrix produc-
tion, deposition, and tissue remodeling.29 Critical illness induces a catabolic response that increases
resting energy expenditure. As systemic inﬂammation persists, organ failure commences, and amino
acids are mobilized from peripheral tissues, often serving as an energy source for the immune system
and wound healing. The catabolic state of critical illness has been linked to the suppression of the
growth hormone-IGF-IGFBP axis.2 Studies evaluating the effects of exogenous IGF-1 administration in
patients with systemic inﬂammatory response syndrome (SIRS) demonstrated low concentrations of
IGF-1 at baseline, with a three-fold increase at 15 min and 10 h post-dosing, returning to baseline at
24 h. Less ill patients have been found to reach peak IGF-1 levels earlier than 10 h after IGF-1
administration, with a more rapid clearance after administration. In addition, IGF-1 treated patients
demonstrate an increase in IGFBP-3 and a decrease in plasma growth hormone levels.7 Patients who
have recovered from acute critical illness appear to have an associated normalization of IGF-1 and
IGFBP-3 levels, as well as a decrease in protease activity. On the other hand, those who fail to recover
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from mechanical ventilation, impaired tissue repair, and atrophy of intestinal mucosa.2
IGF-1 and neuronal changes in critical care (delirium and asphyxia)
Eighty percent of mechanically ventilated patients experience delirium, which is associated with
numerous adverse outcomes such as prolonged hospitalization, increased costs, increased mortality,
and persistent cognitive impairment.33 In addition to advanced age, prior cognitive impairment,
a variety of drugs, severe physical illness, and other inﬂammatory and anti-inﬂammatory markers,
a deﬁcit in IGF-1 has been suggested to play a role in the pathogenesis of delirium in the critically ill. A
recent, preliminary investigation performed on critically ill mechanically ventilated patients went
further to investigate this theory and found no association between IGF-1 levels and the duration of
normal mental state, measured as days without delirium.34 Primarily, it seems that the regulatory
effect of IGF-1 on inﬂammatory cytokines, such as interleukins, serves as a neuroprotector.2 Patients
who develop asphyxiation are also thought to have decreased levels of IGF-1, which again supports the
suggestion that IGF-1 plays a neuroprotective role.35
IGF-1 in wound healing
In burn injury, and likely other forms of severe injury, the wound healing process is a key deter-
minant of patient outcomes.36 Wound healing is a complex process that is affected by many growth
factors, particularly IGF-1 bound to IGFBP.11 This growth factor has receptors on ﬁbroblasts and ker-
atinocytes, which stimulate proliferative activity and mitogenicity, as well as stimulate local collagen
formation, thus creating IGF-1’s wound healing effects.37,38 The ﬁbroblast and keratinocyte prolifera-
tion and ﬁbroblast amino acid uptake that occurs with wounds have also been found to be increased in
IGF-1 enriched cell cultures.39–41 In addition, IGF-1 and other growth factors modulate epidermal and
dermal cell survival and regeneration,29 with high levels of IGF-1 identiﬁed below the wound and at
wound edges.11
It has also been demonstrated that IGF-1 gene transfection (with expression under the control of
the cytomegalovirus promoter) leads to more rapid wound re-epithelialization, prevents muscle
proteinwasting, and preserves total body weight after thermal injury.17 IGF-1 cDNA transfer appears to
facilitate this process by increasing local VEGF, FGF, and KGF concentrations, leading to the develop-
ment of neo-angiogenesis and neo-vascularization in injured skin. Gene transfer also does not appear
to increase types I or III collagen, but does increase type IV collagen, which is expressed in the early
stages of re-epithelialization.11 In addition, IGF-1 gene transfer has been found to increase the amount
of anti-inﬂammatory cytokines in wounds, as well as decrease pro-inﬂammatory cytokine levels. This
has led to the suggestion that this growth factor potentially facilitates the reduction of apoptotic
outcomes to ultimately promote the reformation of skin epithelium.19
Recombinant human Growth Hormone
Growth Hormone (GH) has been used in the treatment of growth deﬁcient children for almost half
a century. The production of GH used to be extremely cumbersome, but the advent of a recombinant
form (recombinant human growth hormone, rhGH) in the mid-1980s made it widely available. At the
same time, advances in the treatment of critically ill patients put more emphasis of the GH/IGF-1
system and led to the use of rhGH in this patient population.
Growth Hormone is a 191-amino acid, single-chain polypeptide hormone, produced in the anterior
pituitary gland. Its release is stimulated by the growth hormone-releasing hormone (Somatocrinin,
GHRH) and inhibited by growth hormone release-inhibiting hormone (Somatostatin, GIH).42 A hall-
mark of GH homeostasis is its pulsatile release pattern with ﬁve to six peaks in a 24 h period. The
production of GH is, moreover, stimulated and inhibited by multiple external and internal regulators.
Stimuli for GH release include hypoglycemia, high insulin levels, stress, exercise, and deep sleep. In
children, periods of rapid growth and elevation of speciﬁc amino acids function as strong stimuli for GH
release. Inhibitors of GH release include hyperglycemia, obesity, and increased glucocorticoid levels.
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these anabolic hormones are expressed in various tissues.43 Stimulation of these receptors in the
skeleton stimulates growth, activation of these receptors in the muscle increases protein synthesis and
decreases glucose uptake.43 Additionally, stimulation of the GH-IGF-1 cascade induces lipolysis in fat
tissue and increases gluconeogenesis in the liver.
Recombinant human growth hormone given at 0.05mg/kg/d has demonstrated beneﬁcial effects on
growth in children suffering from Turner’s syndrome.44 Long-term rhGH treatment of patients with
Turner’s syndrome resulted in an increased ﬁnal height and weight. Additionally, hormone replace-
ment therapy with rhGH improved the quality of life in these patients when compared to patients
without hormone therapy.45 Studies in similar conditions, such as children born small for gestational
age, conﬁrmed the efﬁcacy of rhGH as a growth promoting agent.46 All these studies have demon-
strated a wide safety margin of rhGH administration; however, patients treated with rhGH should be
monitored long-term for possible side effects such as pseudotumor cerebri, gynecomastia, alterated
lipid proﬁles, and hyperglycemia.
Growth Hormone in critically ill patients
Growth Hormone is a powerful anabolic hormone that can potentially ameliorate or reverse the
hypermetabolism and catabolism of critically ill patients. In these patients, both protein synthesis and
breakdown are upregulated, leading to a net negative nitrogen balance associated with muscle
wasting, prolonged need for mechanical ventilation, impaired wound healing and immune response.47
Many authors argue that in critical illness, this protein catabolism can be, at least partly, explained by
acquired resistance to GH. Van den Berghe et al.,48–51 on the contrary, argued that a deﬁciency of, rather
than insensitivity to, GH contributes to the proteinwasting in critically ill. Beneﬁts of rhGH application
to critically ill patients were, until 1999, reported only in a number of smaller controlled clinical
studies. In a prospective, randomized, placebo-controlled trial, Voerman et al.17 administered rhGH
(0.1 mg/kg/day) for 8 days in 20 patients with septic shock receiving parenteral nutrition. He reported
an improved nitrogen balance, but also increased insulin resistance.52 The same group performed
a prospective trial in 18 non-septic patients and reported comparable IGF-1 levels and improved
nitrogen balance.53 Knox et al.54 examined the effects of rhGH in a prospective, uncontrolled study of
53 surgical patients who were dependent on mechanical ventilation. These patients received rhGH
after they failed weaning protocols for a mean time of 38 days. As a major outcome, over 80% of these
patients could be successfully weaned, and the overall survival was 76%. The actual mortality was lower
than predicted by APACHE II scores (24% versus 42%, p < 0.05).54 Another small prospective,
randomized, placebo-controlled trial with the use of rhGH was performed by Pichard et al. in 20
patients with acute respiratory failure.55 These patients required mechanical ventilation for more than
1 week and were randomized to a 12-day treatment with either rhGH (0.14 mg/kg/day) or placebo. The
authors showed a marked nitrogen retention, but no improvement in muscle strength or shorter
duration of ventilatory supports.
In 1999, Jukka Takala and Esko Ruokonen performed a pair of prospective, randomized, placebo-
controlled trials that profoundly changed the use of rhGH in critically ill patients.56 The two studies
were designed as multi-center international trials and included 532 critically ill patients (247 for the
Finnish study and 285 for the European study) who had spent more than 7 days in the ICU. The patients
who had been randomized to receive rhGH therapy were given 16 IU (under sixty kg) or 24 IU (over
sixty kg) rhGH once daily in the morning. The therapy was continued during the ICU stay, but for not
more than 21 days. The primary outcome of the study was the duration of stay in the ICU. Secondary
outcomes included length of mechanical ventilation, length of hospital stay, incidence and clinical
course of organ failures, grip strength, exercise tolerance, overall nitrogen balance, and mortality. The
authors reported no differences in general demographics, organ failure patterns (respiratory, gastro-
intestinal and cardiovascular failure). The administration of rhGH led to increased blood levels of IGF-1,
decreased blood levels of its binding protein-1 and increased levels of its binding protein-3. An
improved nitrogen balance was also found in both arms of the study. The main unexpected ﬁnding of
the trial, however, was that administration of rhGHwas associated with a marked increase in mortality
in the rhGH group (39% in the Finnish study and 44% in the multinational study) versus the placebo
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persisted at the 6 month timepoint, and was independent from APACHE II scores, the primary diag-
nosis, age and gender.
Unsurprisingly, the results of this well-designed and controlled clinical trial led to all but a cessation
of the use of rhGH in critically ill patients. A heated debate between themain study groups followed the
1999 Takala article, with the main objective of elucidating the cause of the massively increased
mortality in the rhGH groups. The speculations were ranging far, including: inadequately high dosage
of rhGH; an insufﬁcient nutritional support, speciﬁcally a lack of glutamine supplementation; insuf-
ﬁcient caloric intake; hyperglycemia and rhGH-induced insulin resistance; prolonged hypercalcemia;
GH resistancewith subsequent supraphysiological levels of GH/IGF-1, leading to ﬂuid retention, edema,
and severe insulin resistance; a hypermetabolic and pro-inﬂammatory effect of rhGH. Schuetz et al.
examined circulating GH levels on admission in a study with 103 consecutive critically ill adult
patients. Circulating GH levels were about 7-fold increased in the 24 non-survivors as compared with
survivors, and showed with a logistic regression analysis that GH and APACHE II/SAPS II scores were
independent predictors of mortality. Interestingly, IGF-1 and IGFBP-3 levels, also measured at
admission, did not correlate with severity of disease or mortality. Median GH levels on admissionwere
similar in septic (n ¼ 53) and non-septic (n ¼ 50) patients.57
The safety debate is ongoing, as more and more authors advocate, in light of the results of Takala
et al.,56 a tailored approach, with the use of rhGH restricted to speciﬁc critically ill patients, such as
burns, selected pediatric patients, convalescent ICU patients, and patients with large trauma.47,58
Meanwhile, it has been found that Ghrelin, a natural ligand for the GH receptor, has orexigenic
effects, stimulates GH secretion, and furthermore plays a role in glucose homeostasis, lipid metabolism
and immune function.59Wu et al. showed in a rodent sepsis model that Ghrelin ameliorates gut barrier
dysfunction in sepsis by vagus nerve activation via central Ghrelin receptors.60 Koch et al. found that
Ghrelin serum concentrations are signiﬁcantly elevated in critically ill patients at admission and that
high Ghrelin levels indicate a favorable prognosis in ICU patients.61 Van den Berghe, ﬁnally, showed in
clinical trial in fourteen critically ill patients that a ﬁve-day continuous infusion with GH-releasing
peptide -2 (a Ghrelin mimetic) and Thyrotropin-releasing hormone resulted in a shift toward
anabolic metabolism, and reactivated blunted GH and TSH secretion, with preserved pulsatility,
peripheral responsiveness, and feedback inhibition.62 Potentially, Ghrelin or Ghrelin-mimetics could
be further developed as agents to protect gut barrier function and improve outcome in sepsis, but
larger randomized studies will be necessary to evaluate its safety and efﬁcacy.
Growth Hormone in burns
The effect of rhGH administration in severely burned children has been initially examined during
the acute phase after burn. A signiﬁcant increase in net protein synthesis and an improved wound
healing have been observed in children treated with 0.2 mg/kg/d rhGH without side effects.63–65
Daily intramuscular administration of recombinant human growth hormone (rhGH) at doses of
0.2 mg/kg as a daily injection during the acute burn phase favorably inﬂuenced the hepatic acute phase
response,66,67 increased serum concentrations of its secondary mediator IGF-I,68 improved muscle
protein kinetics, maintained muscular growth,69,70 decreased donor site healing time by 1.5 days,63
improved resting energy expenditure and attenuated hyperdynamic circulation.71 These beneﬁcial
effects of rhGH are mediated by Insulin-like growth factor (IGF) -I and patients receiving treatment,
demonstrated 100% increases in serum IGF-I and IGFBP-3 relative to healthy individuals.56,72
In a summary of clinical application of rhGH in three different doses (0.05, 0.1 and 0.2 mg/kg/d) over
a prolopnged period of time (up to one year after burn injury), the authors found that an administration
markedly improved growth and lean body mass, while hypermetabolism was signiﬁcantly attenu-
ated.71 Serum GH, IGF-I, and IGFBP-3 were signiﬁcantly increased, while percent body fat content
signiﬁcantly decreased when compared with placebo. A subset analysis revealed most lean body mass
gain in the 0.2 mg/kg group. Bone mineral content showed an unexpected decrease in the 0.2 mg/kg
group, along with decreased PTH and increased osteocalcin level. Resting energy expenditure
improved with rhGH administration, most markedly in the 0.1 mg/kg/d rhGH group, while cardiac
output was decreased at 12 and 18 months post-burn in the rhGH group. An interesting ﬁniding was
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rhGH was associated with an increase in mortality in severely burned children.65,71
Summary
In summary, IGF-1 is an anabolic agent thatmediates the indirect effects of growthhormoneuse, such
as lipolysis and sodium retention. In combination with binding protein, IGF-1 also stimulates muscle
protein synthesis, particularly in burn patients.2 While it may have some associated side effects, these
seem to be negated when bound to IGFBP-3. Many questions still remain regarding its mechanism and
long-term use, but its positive effects on wound healing, burn injury, shock and sepsis remain encour-
aging. The Growth Hormone Research Society recommended the cessation of rhGH (and by inference
IGF-1) use during critical illness.73 This statement has resulted in a question of the beneﬁt of low dose
rhGHuse in non-critically ill patients and the role of enteral support as an adjunct to anabolic treatment.
Despite this current stance on the use of IGF-1 and rhGH in the ICU setting, it has been found that in
catabolic patients, anabolic hormone treatment results in improved whole-body and isolated-limb
protein balance. This knowledge suggests that anabolic therapy may still be appropriate in conjunc-
tionwith enteric nutritional support.7 Finally, regulators of the IGF-1/GHaxis and theGH –receptor, such
as Ghrelin, may play a more important role in the treatment of prolonged critical illness.
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